Tandem Diabetes (TNDM) Tops Q4 EPS by 22c ; Offers Guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/16/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Tandem Diabetes Care (TNDM) PT Lowered to $35 at Citi
February 27, 2025 5:42 AM ESTCiti analyst Joanna Wuensch lowered the price target on Tandem Diabetes Care (NASDAQ: TNDM) to $35.00 (from $50.00) while maintaining a Buy rating.
The analyst comments "Tandem delivered 4Q24 revenue that was modestly higher than expectations, delivering $252.4M (up 20.6%) ahead of consensuss $249.7M,... More
